Tradestie Institutional Equity Comparison Engine

CRESY vs HHS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRESY Overall Edge

CRESY Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cresud SA (CRESY) driven by superior Growth & Margin, Options & Structure while HHS counters with relative strength in Valuation, Momentum & Technical. Fundamentally, CRESY trades at 56.6x Forward P/E with 19.3% operating margin (+20.4% YoY revenue) versus HHS at 14.3x Forward P/E and -3.2% operating margin (-1.7% YoY). In options structure, CRESY sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against HHS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner HHS
CRESY 56.6x vs HHS 14.3x Fwd P/E
Growth & Margin Winner CRESY
Op Margin 19.3% vs -3.2% ยท YoY +20.4% vs -1.7%
Momentum & Technical Winner HHS
1Y -20.3% vs +9.1% ยท 52W Pos 8% vs 69%
Options & Structure Winner CRESY
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (N/A IV)
CRESY NASDAQ
Cresud SA
Real Estate
$9.17
-5.85% 1D
Market Cap $690.8M
1M Return -20.4%
1Y Return -20.26%
Forward P/E 56.6x
Unified AI Score
54.6 / 100 HOLD
Tech 75.0 Fund 55.0 Flow 50.0 Mom 50.0
HHS US Equity
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.85
-3.99% 1D
Market Cap $29.9M
1M Return -10.26%
1Y Return +9.07%
Forward P/E 14.3x
Unified AI Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRESY -20.26% HHS +9.07% Spread: +55.35 pp (HHS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRESY TTM Op. Margin: 19.3% HHS TTM Op. Margin: -3.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRESY vs HHS. Trailing 12-month operating profitability (CRESY 19.3% vs HHS -3.2%) and valuation multiples (CRESY 56.6x vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRESY (6) vs HHS (4)
Institutional Metric CRESY HHS Criterion Row Winner
Market Capitalization Scale $690.8M $29.9M Larger Scale CRESY
Trailing P/E Ratio Valuation 6.3x 14.3x Lower Multiple CRESY
Forward P/E Ratio Valuation 56.6x 14.3x Lower Multiple HHS
Revenue Growth (YoY) Growth +20.4% -1.7% Higher Growth CRESY
Operating Margin (TTM) Profitability 19.3% -3.2% Higher Margin CRESY
Net Profit Margin Profitability 9.6% -3.7% Higher Margin CRESY
Return on Equity (ROE) Capital Efficiency 8.6% -30.4% Higher ROE CRESY
52-Week Range Position Momentum 8% ($9โ€“$14) 69% ($2โ€“$5) Stronger Trend HHS
Beta / 30D Volatility Risk Regime 0.82ฮฒ ยท 59% Vol 0.49ฮฒ ยท 46% Vol Lower Realized Risk HHS
Unified Institutional Score Composite Signal 54.6 / 100 (HOLD) 61.8 / 100 (BUY) Higher Composite HHS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRESY vs HHS Buy Guide
CRESY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live CRESY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HHS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live HHS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRESY nor HHS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.